By IDSE News Staff
On the heels of a shortage of nirsevimab (Beyfortus, Sanofi) for infant respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at the highest risk of developing serious RSV LRTI, according to data reported at the ATS 2024 International Conference, in San Diego (session C17 https://www.abstractsonline.com/pp8/#!/11007/presentation/4607).
“Timely identification of infants at highest risk of